glimepiride has been researched along with linagliptin in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (65.38) | 24.3611 |
| 2020's | 9 (34.62) | 2.80 |
| Authors | Studies |
|---|---|
| Jermendy, G | 1 |
| Paquot, N; Scheen, AJ | 1 |
| Bhattacharya, S; Dugi, KA; Gallwitz, B; Patel, S; Rauch, T; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Christensen, M; Knop, FK | 1 |
| Barnett, AH; Harper, R; Patel, S; Thiemann, S; Toorawa, R; von Eynatten, M; Woerle, HJ | 1 |
| Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P | 1 |
| Shannon, RP | 1 |
| Emser, A; Gallwitz, B; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Bhattacharya, S; Boehm, BO; Grill, V; Johansen, OE; Patel, S; Torjesen, PA; Wetzel, K; Woerle, HJ | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Dugi, KA; Gallwitz, B; Hehnke, U; Mehlburger, L; Patel, S; Rosenstock, J; von Eynatten, M; Woerle, HJ | 1 |
| Barnett, AH; Gallwitz, B; Groop, PH; Hehnke, U; Laakso, M; Patel, S; Rosenstock, J; Tamminen, I; von Eynatten, M; Woerle, HJ | 1 |
| Bluhmki, E; Espeland, MA; Johansen, OE; Kahn, SE; Kastelein, JJ; Lachin, JM; Marx, N; Mattheus, M; Patel, S; Rosenstock, J; Ryckaert, B; Woerle, HJ; Zinman, B | 1 |
| Berk, A; Chilton, R; Esmaeili, H; Jax, T; Marx, N; Stirban, A; Terjung, A; Thiemann, S; von Eynatten, M | 1 |
| Biessels, GJ; Espeland, MA; Janssen, J; Johansen, OE; Mattheus, M; van den Berg, E; Zinman, B | 1 |
| Hansen, T; Hædersdal, S; Knop, FK; Sidelmann Christensen, A; Storgaard, H; Vilsbøll, T | 1 |
| Franklin, JM; Gopalakrishnan, C; Martin, D; Patorno, E; Schneeweiss, S | 1 |
| Abbracchio, MP; Candeias, E; Ceruti, S; Darsalia, V; Duarte, AI; Kehr, J; Klein, T; Lietzau, G; Magni, G; Nyström, T; Patrone, C; Pettersson, H; Skogsberg, J; Yoshitake, T | 1 |
| Kraaijenhof, J; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; van Raalte, DH | 1 |
| Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; Touw, DJ; van Raalte, DH | 1 |
| Andersen, KR; Espeland, MA; Johansen, OE; Kadowaki, T; Keller, A; Marx, N; Mattheus, M; McGuire, DK; Pratley, RE; Rosenstock, J; Seino, Y; Weber, M; Zinman, B | 1 |
| Aly, A; Davey, M; Elbeddini, A; Erickson, D; Gallinger, J; Hooda, N; Lee, S; Tayefehchamani, Y | 1 |
| Biessels, GJ; Espeland, MA; Janssen, J; Johansen, OE; van den Berg, E; Verhagen, C; Wallenstein, G; Zinman, B | 1 |
| Danser, AHJ; Hartmann, B; Holst, JJ; Joles, JA; Kramer, MHH; Muskiet, MHA; Ouwens, DM; Smits, MM; Tonneijck, L; van Raalte, DH | 1 |
| Darsalia, V; Elabi, OF; Karampatsi, D; Klein, T; Lietzau, G; Nyström, T; Patrone, C; Paul, G; Vercalsteren, E | 1 |
| Espeland, MA; Kolkailah, AA; Lund, SS; Marx, N; Mattheus, M; McGuire, DK; Pfarr, E; Rosenstock, J | 1 |
1 review(s) available for glimepiride and linagliptin
| Article | Year |
|---|---|
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
17 trial(s) available for glimepiride and linagliptin
| Article | Year |
|---|---|
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Research Design; Sulfonylurea Compounds; Treatment Failure; Treatment Outcome | 2012 |
Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Metformin; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome | 2012 |
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.
Topics: Analysis of Variance; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds; Treatment Outcome; Weight Gain | 2013 |
C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study.
Topics: Adult; Aged; Autoimmunity; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Sulfonylurea Compounds | 2014 |
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Purines; Quinazolines; Risk; Sulfonylurea Compounds; Time Factors; Young Adult | 2015 |
Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: a 52-week, randomized, double-blind clinical trial.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Sulfonylurea Compounds | 2015 |
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Protocols; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Incretins; Linagliptin; Male; Middle Aged; Patient Selection; Research Design; Risk Factors; Sample Size; Sulfonylurea Compounds; Treatment Outcome | 2015 |
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
Topics: Aged; Biomarkers; Brachial Artery; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Microcirculation; Microvessels; Middle Aged; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Vasodilation | 2017 |
Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus.
Topics: Aged; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Research Design; Sulfonylurea Compounds; Treatment Outcome | 2018 |
Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Cross-Over Studies; Denmark; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Hepatocyte Nuclear Factor 1-alpha; Humans; Hypoglycemic Agents; Linagliptin; Patient Reported Outcome Measures; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Treatment Outcome | 2018 |
Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Double-Blind Method; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Linagliptin; Overweight; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Effects of DPP-4 Inhibitor Linagliptin Versus Sulfonylurea Glimepiride as Add-on to Metformin on Renal Physiology in Overweight Patients With Type 2 Diabetes (RENALIS): A Randomized, Double-Blind Trial.
Topics: Adult; Aged; Chemokine CXCL12; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Kidney; Linagliptin; Male; Metformin; Middle Aged; Natriuresis; Overweight; Sulfonylurea Compounds; Treatment Outcome | 2020 |
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Middle Aged; Sulfonylurea Compounds; Treatment Outcome | 2021 |
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study.
Topics: Aged; Blood Glucose; Cognition; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Neuropsychological Tests; Sulfonylurea Compounds; Treatment Outcome | 2021 |
Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Double-Blind Method; Glycated Hemoglobin; Hemodynamics; Humans; Hypoglycemic Agents; Linagliptin; Sulfonylurea Compounds; Treatment Outcome | 2022 |
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulins; Linagliptin; Treatment Outcome | 2023 |
8 other study(ies) available for glimepiride and linagliptin
| Article | Year |
|---|---|
Gliptin versus a sulphonylurea as add-on to metformin.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2012 |
Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Metformin; Purines; Quinazolines; Sulfonylurea Compounds | 2012 |
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Male; Mice; Obesity; Purines; Quinazolines; Stroke; Sulfonylurea Compounds | 2013 |
DPP-4 inhibition and neuroprotection: do mechanisms matter?
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Stroke; Sulfonylurea Compounds | 2013 |
Using Real-World Data to Predict Findings of an Ongoing Phase IV Cardiovascular Outcome Trial: Cardiovascular Safety of Linagliptin Versus Glimepiride.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Glycated Hemoglobin; Humans; Linagliptin; Medicare; Middle Aged; Sulfonylurea Compounds; Treatment Outcome; United States | 2019 |
Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging.
Topics: Aging; Animals; Corpus Striatum; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Dopamine; Linagliptin; Male; Mice; Mice, Inbred C57BL; Models, Animal; Parkinson Disease; Risk; Substantia Nigra; Sulfonylurea Compounds | 2020 |
Fournier's gangrene with dapagliflozin in a rural hospital: a case report.
Topics: Abscess; Accidental Falls; Aged; Anti-Bacterial Agents; Benzhydryl Compounds; Debridement; Diabetes Mellitus, Type 2; Drainage; Female; Fournier Gangrene; Glucosides; Hospitals, Rural; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Obesity; Perineum; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2021 |
DPP-4 Inhibitor and Sulfonylurea Differentially Reverse Type 2 Diabetes-Induced Blood-Brain Barrier Leakage and Normalize Capillary Pericyte Coverage.
Topics: Animals; Blood-Brain Barrier; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Mice; Pericytes; Sulfonylurea Compounds | 2023 |